China Research and Intelligence (CRI) has emerged to provide high-level research and advisory services to all those with keen interest in different Chinese markets and industries. The firm, founded in 2007, is headquartered in Shanghai, China. Their team’s principle goal is to present the most helpful and reliable insights and information, sincerely serving a broad choice of multinational and local customers with their business practice and ethics.
CRI’s reports are packed with precise analysis of key market indicators, strategic recommendations from industry experts, market estimated figures, projections, reviews of competitive strategies, consumers investigation, reviews of business models, market share analyses, key forces driving of restraining market growth.
CRI’s scope of offerings encircles numerous market research reports, industry analytical reviews, company business reports, industry-specific research databases. Further, the company also offers outsource and custom-tailored services for research organisations, and multiple report readers.
Publications found:
1,023
Sort by:
Research Report on China's Alectinib Market, 2021-2025
US$ 2,600.00
Lung cancer is the most common type of cancer and the leading cause of cancer deaths. 4.57 million new cancer cases were reported in China in 2020, including 820,000 lung cancer cases. 3 million cance...
September 2021
40 pages
Research Report on China's Anastrozole Market, 2021-2025
US$ 2,600.00
According to IARC’s 2020 World Cancer Report, the number of new cases of breast cancer reached 2.26 million in 2020, larger than that of lung cancer cases which was 2.2 million. Breast cancer has beco...
September 2021
40 pages
Research Report on China's Escitalopram Market, 2021-2025
US$ 2,600.00
Depression is the fourth leading disease in the world and is expected to become the first by 2030. However, the medical prevention and treatment of depression in China is still of low recognition rate...
September 2021
40 pages
Research Report on China's Exemestane Market, 2021-2025
US$ 2,600.00
Breast cancer is a common malignant tumor in menopausal women, and now ranks first among malignant tumors in women. Recently, the number of breast cancer patients in China has been increasing year by...
September 2021
40 pages
Research Report on China's Gefitinib Market, 2021-2025
US$ 2,600.00
Lung cancer is the most common type of cancer and the leading cause of cancer deaths. 19.29 million new cancer cases were diagnosed worldwide in 2020, 4.57 million of which were in China, accounting f...
September 2021
40 pages
Research Report on China's Levetiracetam Market, 2021-2025
US$ 2,600.00
Epilepsy is second only to stroke as a common chronic neurological disorder characterized by excessive neuronal discharge in the brain resulting in recurrent, seizure and transient central nervous sys...
September 2021
40 pages
Research Report on China's Lobaplatin Market, 2021-2025
US$ 2,600.00
According to IARC of WHO, globally, there were 19.29 million new cases of cancer in 2020, among which 2.26 million were cases of breast cancer, surpassing the 2.2 million cases of lung cancer. Breast...
September 2021
40 pages
Research Report on China's Mesalazine Market, 2021-2025
US$ 2,600.00
Inflammatory bowel disease (IBD) is a chronic disease of the digestive system with unclear etiology, difficulty to cure, and recurrent attacks with multiple complications. The incidence of IBD in Chin...
September 2021
40 pages
Research Report on China's Nicorandil Market, 2021-2025
US$ 2,600.00
In China, the crude incidence rate of hypertension among residents over the age of 18 is close to 30%, and the most common hazard of hypertension is coronary heart disease. By the end of 2020, it is e...
September 2021
40 pages
Research Report on China's Roxatidine Market, 2021-2025
US$ 2,600.00
Peptic ulcers and gastrointestinal bleeding are common diseases in China with a large number of patients. Due to the fast pace of modern life, accelerated urbanization and great mental stress, the num...
September 2021
40 pages
Research Report on China's Sorafenib Market, 2021-2025
US$ 2,600.00
Hepatocellular carcinoma (HCC) is the most common type of chronic liver cancer in adults and the most common cause of death in patients with cirrhosis. Hepatocellular carcinoma (HCC) is the third most...
September 2021
40 pages
Research Report on China's Venlafaxine Market, 2021-2025
US$ 2,600.00
Depression is the result of a complex interplay of social, psychological and physical factors. People who experience adverse events in their lives are more likely to develop depression. Depression can...
September 2021
40 pages
Research Report on China's Zoledronic Acid Market, 2021-2025
US$ 2,600.00
Osteoporosis is a metabolic disease caused by a combination of endocrine, nutritional, immune, and genetic factors, and is characterized by increasing bone fragility and fracture due to a gradual decr...
September 2021
40 pages
Investigation Report on China's Iohexol Market 2021-2025
US$ 2,600.00
Iohexol is a non-ionic X-ray contrast agent. Iohexol injection is suitable for intravascular and intracavitary injections in adults and children. In clinical angiography (cerebrovascular angiography,...
July 2021
50 pages
Investigation Report on China's Linezolid Market 2021-2025
US$ 2,600.00
Linezolid is an oxazolidinone antibiotic, mainly used to treat infections caused by gram-positive (G+) cocci, including suspected or confirmed hospital-acquired pneumonia (HAP) caused by methicillin-r...
July 2021
50 pages
Investigation Report on China's Metformin Market 2021-2025
US$ 2,600.00
Metformin is the first-line drug for the treatment of type 2 diabetes, especially in people who are overweight. Metformin was originally developed by Merck Sharp & Dohme (trade name: GLUCOPHAGE ). GLU...
July 2021
50 pages
Investigation Report on China's Nifedipine Market 2021-2025
US$ 2,600.00
Nifedipine is a dihydropyridine calcium channel blocker, which is mainly used to bind to L-type calcium channels. Nifedipine is mainly used to treat chronic stable angina pectoris, vasospasm angina pe...
July 2021
50 pages
Investigation Report on China's Octreotide Market 2021-2025
US$ 2,600.00
Octreotide is a derivative of artificially modified natural somatostatin, which is an octapeptide. Its physiological effects include inhibiting growth hormone function, inhibiting the secretion of gas...
July 2021
50 pages
Research Report on China's Mecobalamin Market, 2021-2025
US$ 2,600.00
Mecobalamin is an endogenous coenzyme B12, which has a good effect on neuronal conduction compared with other types of vitamin B12, and can promote nucleic acid-protein-lipid metabolism through methyl...
July 2021
50 pages
Investigation Report on China's Anlotinib Market 2021-2025
US$ 2,600.00
Anlotinib is an oral multi-targeting small-molecule tyrosine kinase inhibitor that can target multiple angiogenic factor receptors to inhibit tumor angiogenesis. It can be used for advanced non-small...
June 2021
50 pages
Investigation Report on China's Goserelin Market 2021-2025
US$ 2,600.00
Goserelin is a synthetic analogue of a naturally occurring gonadotropin-releasing hormone (GnRH). Goserelin is developed by AstraZeneca, is mainly used to treat advanced breast and prostate cancer. In...
June 2021
50 pages
Investigation Report on China's Docetaxel Market 2021-2025
US$ 2,600.00
Docetaxel, sold under the brand name Taxotere, is a paclitaxel anti-tumor drug used for the treatment of locally advanced or metastatic non-small cell lung cancer. Docetaxel injection was first develo...
June 2021
50 pages
Investigation Report on China's Omalizumab Market 2021-2025
US$ 2,600.00
Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE). At the end of 2017, the FDA approved the registration of Novartis Europh...
June 2021
50 pages
